Hillsdale Investment Management Inc. Increases Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

Hillsdale Investment Management Inc. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 4.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 743,679 shares of the company’s stock after purchasing an additional 29,150 shares during the quarter. Hillsdale Investment Management Inc. owned approximately 0.24% of Amneal Pharmaceuticals worth $9,244,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of AMRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Amneal Pharmaceuticals by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock worth $793,000 after purchasing an additional 4,178 shares during the last quarter. Millennium Management LLC grew its holdings in Amneal Pharmaceuticals by 32.6% during the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock valued at $17,492,000 after buying an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Amneal Pharmaceuticals during the 1st quarter valued at $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Amneal Pharmaceuticals by 5.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock worth $2,807,000 after buying an additional 16,536 shares in the last quarter. Finally, Creative Planning increased its position in Amneal Pharmaceuticals by 61.9% during the second quarter. Creative Planning now owns 23,896 shares of the company’s stock worth $193,000 after buying an additional 9,136 shares in the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. UBS Group began coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 price objective on the stock. Weiss Ratings cut Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, Barclays upped their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.80.

Insiders Place Their Bets

In related news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director directly owned 93,660 shares in the company, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $17.18 on Tuesday. The stock has a fifty day moving average of $14.73 and a two-hundred day moving average of $13.77. The company has a market capitalization of $5.48 billion, a PE ratio of 45.21 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $7.66 and a fifty-two week high of $17.86.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million for the quarter. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.